{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:19:32Z","timestamp":1770977972126,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.ejps.2006.01.001","type":"journal-article","created":{"date-parts":[[2006,2,11]],"date-time":"2006-02-11T12:14:40Z","timestamp":1139660080000},"page":"86-95","source":"Crossref","is-referenced-by-count":87,"title":["Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases"],"prefix":"10.1016","volume":"28","author":[{"given":"Bin","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Bin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Dong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruo-Bing","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejps.2006.01.001_bib1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1023\/A:1011975120776","article-title":"Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats","volume":"15","author":"Bargoni","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2006.01.001_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/03602538608998294","article-title":"Pharmacokinetics of mitoxantrone in man and laboratory animals","volume":"17","author":"Batra","year":"1986","journal-title":"Drug Metabol. Rev."},{"key":"10.1016\/j.ejps.2006.01.001_bib3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0753-3322(01)00141-X","article-title":"Breast cancer chemoprevention: current clinical practice and future direction","volume":"55","author":"Bevers","year":"2001","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejps.2006.01.001_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0955-2863(02)00230-9","article-title":"Fattic acid modulation of human MCF-7 breast cancer cell proliferation, apoptosis and differentiation","volume":"13","author":"Chamras","year":"2002","journal-title":"J. Nutr. Biochem."},{"issue":"10","key":"10.1016\/j.ejps.2006.01.001_bib5","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2199::AID-CNCR23>3.0.CO;2-T","article-title":"Methotrexate bound to carbon particles used for treating cancers with lymph node metastases in animal experiments and a clinical pilot study","volume":"78","author":"Hagiwara","year":"1996","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejps.2006.01.001_bib6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1023\/A:1012117531448","article-title":"Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake","volume":"14","author":"Hawley","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2006.01.001_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0378-4347(00)83783-4","article-title":"Novel assay method for mitoxantrone in plasma and its application in cancer patients","volume":"532","author":"Hu","year":"1990","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.ejps.2006.01.001_bib8","series-title":"Oncology of Mammary Gland","first-page":"1","year":"2000"},{"issue":"5","key":"10.1016\/j.ejps.2006.01.001_bib9","first-page":"32","article-title":"Determination of entrapment rate and entrapment yield of mitoxantrone solid lipid nanoparticles","volume":"5","author":"Lu","year":"2004","journal-title":"Drug Stand. China"},{"key":"10.1016\/j.ejps.2006.01.001_bib10","series-title":"Design and Analysis of Experiments","first-page":"445","article-title":"Response surface methodology","author":"Montgomery","year":"1984"},{"key":"10.1016\/j.ejps.2006.01.001_bib11","first-page":"62","article-title":"Solid lipid nanoparticles (SLN). An alternative colloidal carrier system for controlled drug delivery","volume":"41","author":"M\u00fcller","year":"1995","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2006.01.001_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0005-2736(97)00221-6","article-title":"The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue local toxicity of two antitumor drugs","volume":"1369","author":"Oussoren","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.ejps.2006.01.001_bib13","first-page":"309","article-title":"Novel method of greatly enhanced delivery of liposomes to lymph nodes","volume":"295","author":"Phillips","year":"2000","journal-title":"J. Parmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2006.01.001_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0378-4347(96)00023-0","article-title":"Determination of mitoxantrone in mouse whole blood and different tissues by high-performance liquid chromatography","volume":"679","author":"Rentsch","year":"1996","journal-title":"J. Chromatogr."},{"issue":"8","key":"10.1016\/j.ejps.2006.01.001_bib15","first-page":"808","article-title":"Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukaemia patients aged 61\u201365 years","volume":"87","author":"Schaich","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.ejps.2006.01.001_bib16","first-page":"194","article-title":"Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol. I. Preparation and particle size determination","volume":"3","author":"Siekmann","year":"1994","journal-title":"Pharm. Pharmacol. Lett."},{"key":"10.1016\/j.ejps.2006.01.001_bib17","series-title":"Targeted Drug Delivery Systems","first-page":"230","article-title":"Studies on mitoxantrone nanospheres for hepatic targeting","author":"Zhang","year":"1997"},{"issue":"1","key":"10.1016\/j.ejps.2006.01.001_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000087242","article-title":"Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis","volume":"54","author":"Zingler","year":"2005","journal-title":"Eur. Neurol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098706000042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098706000042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T13:57:01Z","timestamp":1547819821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098706000042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":18,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0928098706000042"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2006.01.001","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}